PT - JOURNAL ARTICLE AU - Stéphane Raffard AU - Sophie Bayard AU - Margot Eisenblaetter AU - Jérôme Attal AU - Christelle Andrieu AU - Isabelle Chereau AU - Guillaume Fond AU - Sylvain leignier AU - Jasmina Mallet AU - Philippe Tattard AU - Mathieu Urbach AU - David Misdrahi AU - Yasmine Laraki AU - Delphine Capdevielle TI - Attitudes towards vaccines, intent to vaccinate and the relationship with COVID-19 vaccination rates in individuals with schizophrenia AID - 10.1101/2022.01.12.22269167 DP - 2022 Jan 01 TA - medRxiv PG - 2022.01.12.22269167 4099 - http://medrxiv.org/content/early/2022/01/17/2022.01.12.22269167.short 4100 - http://medrxiv.org/content/early/2022/01/17/2022.01.12.22269167.full AB - Background People with schizophrenia are at high risk for developing severe COVID-19 outcomes but recent evidence suggests that this population have lower vaccination rates than the general population. This gap in vaccination rates could be explained by attitudinal and structural barriers.Aims This study explored the role of potential attitudinal barriers by comparing schizophrenia patients with participants from the general population regarding COVID-19 vaccination rates, general attitudes towards vaccines, and willingness to take a COVID-19 vaccine.Method We conducted a cross-sectional study between April 2021 and October 2021. 100 schizophrenia patients and 72 controls were recruited. Attitudes towards vaccines were assessed with the Vaccination Attitudes Examination Scale. COVID-19 vaccination rates, sociodemographic, clinical and health-related variables were also assessed.Results In our study, the proportion of individuals with schizophrenia were under-vaccinated despite similar general attitudes towards vaccination and higher willingness to be vaccinated against COVID-19 compared to the participants from the general population. In patients, negative attitudes toward vaccines was related to higher level of negative psychotic symptoms and higher level of paranoid ideation. As a whole, participants with more negative attitudes towards vaccines were less likely to be vaccinated against COVID-19 and had lower levels of trust in institutions.Conclusions Vaccine hesitancy does not appear to be a major barrier for COVID-19 vaccine uptake amongst people with schizophrenia. This study suggests that disparities in COVID-19 vaccination rates in schizophrenia do not seem related to attitudinal but rather structural barriers.Significant outcomesIn both groups, non-vaccinated individuals had higher general negative attitudes towards vaccines.People with schizophrenia were under-vaccinated (64% versus 77.8%) despite similar general attitudes towards vaccination and higher willingness to be vaccinated in non vaccinated against COVID-19 compared to the controls (41.7% versus 21.5%).General positive attitudes towards vaccines were negatively associated with persecutory ideation and negative symptoms in patients.LimitationsOur two sample groups sere composed exclusively of French individuals, potentially limiting the generalizability of our results.The cross-sectional design of our study.Competing Interest StatementThe authors have declared no competing interest.Funding StatementANR Grant, (SCHIZOVAC; ANR-21-COVR-0017) Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:CHU Montpellier IRB ID: 202100768 I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors